The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain "BETA"
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The main purpose of the trial is to identify biomarkers from the blood as well as
electrophysiologic and morphometric features (chemical, electrophysiologic and ultrasound
biomarkers) that reflect the intensity of pain and/or foretell the efficacy of
pharmacological (non-surgical) treatment in patients with acute low back pain.
Phase:
Phase 3
Details
Lead Sponsor:
Semmelweis University
Collaborators:
MEDITOP Pharmaceutical LTD, Hungary National Research Develpment and Innovation Fund, Hungary